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BACKGROUND: 2-[18F]-Fluoro-2-Deoxy-D-Glucose (FDG-PET) is a well established functional imaging modality for the initial 
staging of Hodgkin lymphoma (HL) in patients from Western Europe and North America. The reliability of FDG-PET in popula-
tions of different ethnic groups is unclear, as all investigations published to date have come from developed countries.
PURPOSE: The aim of the present study was to investigate the effectiveness of FDG-PET in the initial staging of HL patients in 
a Brazilian population.
METHODS: Eighty-two patients with newly diagnosed HL were prospectively included in the study. All patients were staged with 
both conventional clinical staging (CCS) methods, including computed tomography (CT) and whole-body FDG-PET methods. A 
standard of reference for the nodal regions and the extranodal organs was determined using all available information, including the 
CCS methods, FDG-PET, the diagnostic histology and the follow-up examinations. The results of the CCS were then compared 
to the FDG-PET results.
RESULTS: The sensitivity of FDG-PET was higher for nodal staging than that of CT (87.8% vs. 61.6%, respectively). FDG-PET 
was also more sensitive than CT in regard to evaluating the extranodal organs for lymphomatous involvement (96.2% vs. 40.0%, 
respectively). FDG-PET detected all 16 patients who were characterized by a positive bone marrow biopsy and identified an ad-
ditional 4 patients with bone marrow disease. The incorporation of FDG-PET coupled with CCS in the staging procedure upstaged 
20% (17/82) of the patients and downstaged 11% (9/82) of the patients. As a result of these changes in staging, 15% (13/82) of the 
patients would have received a different therapeutic regimen.
CONCLUSIONS: The FDG-PET method is superior to CT for the detection of nodal and extra-nodal HL. The observation that 
the FDG-PET method upstaged the disease was the most common result (20% of patients) brought about by the addition of PET 
to the staging algorithm, even in a population of patients with a high incidence of advanced disease. However, changes in stages 
based on FDG-PET results should be confirmed by biopsy.
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INTRODUCTION
Over the last several decades, the Hodgkin lymphoma 
(HL) cure rates have remained among the highest in 
oncologic patients, mainly due to the improvement of 
treatment strategies, which include chemotherapy and 
radiotherapy. A precise staging of HL patients is essential 
for selecting an appropriate treatment, as well as for 
determining the prognosis. The Ann-Arbor system modified 
in Cotswolds1 is widely used to define the conventional 
clinical stage (CCS) of HL patients.
Conventional staging procedures include a physical 
examination, computed tomography (CT), and a bone 
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marrow (BM) biopsy. Although CT provides important 
anatomic details, it cannot reliably distinguish between 
malignant and benign lesions because the definition of 
nodal or organ involvement is based only on morphological 
criteria. The correlation of CT findings with pathological 
staging demonstrated that the size of the lymph nodes 
was not always associated with the presence of HL.2 In 
addition, CT has a limited sensitivity for the detection of 
splenic, hepatic and bone marrow involvement. Therefore, 
the clinical staging of patients may be underestimated and 
thus lead to inappropriate therapy, or clinical staging may 
overestimate the severity and lead to overtreatment.
In recent years, positron emission tomography (PET) 
with 2-[18F]-fluoro-2-Deoxy-D-glucose (FDG) has become 
an established modality for staging HL in the United States 
and Europe.3-6 Besides HL staging, FDG-PET is also 
useful for evaluating the treatment response and the post-
treatment remission status of HL patients, both of which 
are matters beyond the scope of this paper. Guidelines 
for its use in lymphomas were recently proposed by an 
international group.7 However, the spectrum of HL varies 
across different ethnic populations and environments, with 
different frequencies of Epstein Barr Virus detectable in 
the tumor, different grades of disease aggressiveness and 
later diagnoses. In developing countries, such as Brazil, the 
incidence of the advanced stages is considerably higher than 
in the United States and Europe.8 Although upstaging of the 
disease is the most common result when PET is integrated 
into the staging procedure, the performance of FDG-PET 
staging in populations with a high frequency of advanced 
HL stages is still unknown.
MATERIAL AND METHODS
Patients
Eighty-two consecutive patients presenting newly 
diagnosed, biopsy proven, classical HL from the Hematology 
Division of the São Paulo University Clinics Hospital were 
eligible for this prospective study performed between 
August 2005 and January 2008. The only exclusion criterion 
was pregnancy. Notably, none of the patients had diabetes 
mellitus. The study was approved by the Ethical Board of the 
São Paulo University Clinics Hospital, and written informed 
consent was obtained from all participating patients.
Conventional staging
All patients were subjected to CCS procedures that 
included a physical examination, complete blood cell counts, 
blood chemistry analysis, CT scans (cervical, thoracic, 
abdomen and pelvic), and a bilateral BM biopsy. CT 
scans were sectioned at a thickness of 5 mm, and oral and 
intravenous contrast agents were administered to all patients. 
The nodal or organ involvement, as determined by CT, was 
defined by the modified Ann Arbor criteria.1 All patients 
had undergone a BM biopsy performed at the posterior iliac 
crest. Bone marrow involvement was defined as positive only 
for cases in which the presence of Reed-Sternberg cells or 
its variants were unequivocally observed. The CCS of each 
patient was assigned according to the Ann Arbor staging 
system.1
FDG-PET Imaging
Whole-body PET images were acquired following a 
60-minute uptake period after the intravenous administration 
of 296 to 444 MBq (8 to 12 mCi) of FDG. Imaging was 
then performed via 2-D acquisition with a GE Advance 
PET scanner (General Electric Medical Systems Advance; 
Milwaukee, Wisconsin, USA). Attenuation correction was 
performed using68 Ge sources. Prior to FDG administration, 
the fasting glucose level was measured in order to verify a 
blood glucose level < 160mg/dL. Diazepam was given orally 
to the majority of patients in order to avoid muscular and 
brown fat uptake.
Visual interpretation of the images was performed 
independently by two experienced observers who were 
not aware of the CCS results. Areas of nonphysiological 
abnormalities increased the FDG uptake over the background 
and were classified as positive for the disease. Nodal and 
extranodal lymphoma involvement was defined according 
to the criteria established by the Consensus of the Imaging 
Subcommittee of International Harmonization Project in 
Lymphoma.7
The time between the staging CT and PET scan was no 
longer than two weeks.
Treatment
All patients were treated based on the CCS, regardless 
of the FDG-PET results. Stage I and II patients were treated 
with four to six cycles of the ABVD regimen (doxorubicin, 
bleomycin, vinblastine and dacarbazine). Stage III patients 
were treated with six to eight cycles of ABVD. Stage 
IV patients were treated with eight cycles of ABVD. 
Radiotherapy was included in all stage I or II patients and 
patients with bulky disease, regardless of their stage. 
Data analysis
In order to establish the diagnostic accuracy of the 
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FDG-PET and the CT results obtained by both methods in 
all of the nodal regions and organs, these results had to be 
compared to a gold standard technique, such as histological 
examination. However, for obvious practical and ethical 
reasons, this was not possible. Instead of the histological 
gold standard, a reference standard was used for this analysis. 
The reference standard for all nodal regions and organs was 
obtained by combining the initial FDG-PET and CT results 
with the results of the FDG-PET performed after the second 
chemotherapy cycle and CT scans performed after the fourth 
cycle of chemotherapy. If the initial FDG-PET and CT scans 
were positive, the region was defined as a true positive for 
lymphoma involvement, while negative findings gleaned 
from both of these initial methods were regarded as a true 
negative. Discordant cases were retrospectively analyzed by 
an interdisciplinary team consisting of radiologists, nuclear 
physicians and hemato-oncologists. The status of a region 
or organ was determined using data from an interim FDG-
PET performed after the second chemotherapy cycle, CT 
scans performed after the fourth cycle, CT and/or FDG-PET 
analyses obtained at the end of treatment, and, if available, a 
biopsy of the suspected lesion. For example, if a small lesion 
(< 1 cm) was radiologically normal and the PET positive 
lymph node changed to PET negative during follow-up 
scans, this lesion was labeled as “committed.” Alternatively, 
a large lymph node was considered “not committed” if it 
was PET negative and did not shrink during treatment while 
other enlarged nodes regressed and were PET negative at the 
end of treatment. To study BM involvement, the FDG-PET 
results were compared with the results of the bilateral BM 
biopsy. Notably, all of these patients had at least one year of 
follow-up evaluation after the completion of chemotherapy.
In the analysis of clinical stage, the results of both 
methods were compared (CCS and FDG-PET alone). This 
analysis indicated that the PET would lead to a change in the 
clinical strategy if the patient stage moved from an early to 
advanced disease stage and vice-versa (either I or II up to III 
or IV or III or IV down to I or II).
The diagnostic accuracies are given in terms of 
sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV). SPSS 10.0 for Windows 




Of the 82 patients evaluated, 40 were male. The median 
age at diagnosis was 32 years (16 to 82 years), and the most 
frequent histological subtype was nodular sclerosis, which 
was observed in 45 (54.8%) of the patients. The demographic 
and clinical characteristics of the patients as well as their 
corresponding CCS methods are listed in Table 1.
Staging accuracy in nodal sites
A total of 535 nodal regions had initial involvement 
according to the reference standard. CT scans could 
detect HL in 336 of the 535 regions analyzed, and FDG-
PET detected involvement in 477 of the 535 regions. The 
observed frequency of nodal disease as a function of the site 
is listed in Table 2. The overall sensitivity, specificity, PPV 
and NPV for nodal staging of CT and FDG- PET/CT are 
provided in Table 4.
Staging accuracy in extranodal sites
The spleen, liver, lungs, bone marrow/bone and soft 
tissue were evaluated. HL was observed in 43 of the 92 
regions analyzed (46.7%) using CT and 86 of the 92 regions 
(93.4%) using FDG-PET. The frequency of involvement 
as a function of the site is listed in Table 3. Table 4 shows 
the sensitivity, specificity, PPV and NPV of the CT and the 
FDG-PET methods for detection of organ involvement.
PET Comparison to BM Biopsy
Of the 82 patients, bilateral BM biopsy indicated marrow 
infiltration in 16 (19.5%) patients. Notably, all of these cases 
Table 1 - Demographic and clinical characteristics of the 
Hodgkin’s lymphoma patients
Characteristics N = 82 (%)
Sex
            Female
            Male
42 (51.2%)
40 (48.8%)
Age – median (range) 32 (16 to 82)
Race
            White
            Black
            Asian






            Nodular sclerosis
            Mixed cellularity
            Lymphocyte rich
            Lymphocyte-depleted






Ann Arbor Clinical Stage
            I
            II
            III





B Symptoms 50 (60.9%)
Bulky Disease 48 (58.5%)
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had multiple focal bone uptake of FDG, including the iliac 
crest region. Five other patients had a positive scan in the 
bone/BM as observed using FDG-PET in conjunction with 
negative BM biopsy results. Three patients had positive 
results in multiple bone/bone marrow areas including the 
posterior iliac crest FDG uptake, while one patient had a 
positive FDG uptake in multiple bone/BM areas but only 
limited uptake in the posterior iliac crest. The other patient 
had only one focal area of uptake located on a costal arch. 
Table 2 - Region-based analysis of lymph nodes sites using 




Cervical 113 100 66
Supraclavicular 107 96 68
Mediastinal 69 68 65
Axillarys 55 49 42




Iliac 17 17 7
Inguinal 32 31 12
Others 25 19 10
TOTAL 535 477 336
Table 3 - Region-based analysis of extranodal sites using CT 




Lungs 29 26 22
Spleen 31 30 14
Liver 8 6 5
Bone/Bone Marrow* 21 21 1
Soft Tissue 3 3 1
TOTAL 92 86 43
* Bones includes bone marrow involvement.
Table 4 - Assessment of the overall accuracy rates using CT 
and FDG-PET on nodal and extranodal sites
Nodal sites Extranodal sites
PET TC PET TC
Sensitivity 87.8% 61.6% 96.2% 40.0%
Specificity 98.8% 99.0% 99.5% 98.7%
PPV* 98.5% 98.2% 97.4% 86.4%
NPV* 90.3% 74.8% 99.2% 86.4%
* PPV: positive predictive value; NPV: negative predictive value.
Of the five patients with PET positive scans in the bone/ 
BM, the latter case was considered as a false positive due 
to the fracture of a costal bone observed on the CT results. 
Regarding the former four patients, two had magnetic 
resonance imaging results indicating focal BM alterations 
compatible with lymphoma infiltration, while another patient 
had bone involvement detected on a bone scintigraphy. In all 
of these patients, the bone/BM FDG-avid lesions disappeared 
in the interim PET scan performed after the second cycle of 
chemotherapy. 
Change in clinical stage and therapy
Upon comparison of both methods used in the staging 
of patients, the method that included the FDG-PET was 
concordant with CCS in 56 (68.2%) of the patients. In these 
concordant cases, additional committed lymph nodes were 
identified by FDG-PET in 48 (85.7%) of the patients. In 26 
(31.7%) patients, the results obtained using FDG-PET scans 
were discordant with CCS. Seventeen patients (20.7%) were 
upstaged, while nine patients (10.9%) were downstaged. Of 
the seventeen upstaged patients, two moved from clinical stage 
I to II, one patient moved from stage I to IV, three patients 
moved from stage II to III, three patients moved from stage 
II to IV, and eight patients moved from stage III to IV. Of the 
nine downstaged patients, one moved from clinical stage II to 
I, four patients moved from stage III to II, one patient moved 
from stage IV to I, one patient moved from stage IV to II, and 
two patients moved from stage IV to III (Table 5). 
If the FDG-PET results were included in the initial 
staging procedure, 13 (15.8%) of the 82 patients would have 
had a change in the therapy strategy. The status of seven 
patients would have been modified from early to advanced 
stages, and six patients would have been modified from 
advanced to early stages. Consequently these patients would 
have received a more or less aggressive treatment regimen, 
respectively (Table 5). 
As an example, Figure 1 shows images of a patient 
upstaged after FDG-PET analysis from stage II to III. The 
PET images demonstrated that FDG-PET positive foci in 
the spleen were not observed in the CT. While the biopsies 
of these lesions were not performed, the FDG positivity in 
the spleen disappeared when an early interim FDG-PET 
was completed after two cycles of chemotherapy (ABVD). 
Therefore, these images were considered FDG-PET true 
positive and CT false negative.
DISCUSSION
The reliability of FDG-PET in populations of different 
ethnic groups has not been investigated, as all studies 
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Table 5 - Initial staging distribution for Conventional Clinical Staging (CCS) and FDG-PET according to the Ann Arbor 
staging system and the corresponding up- and down-staging 
PET Stage I PET Stage II PET Stage III PET Stage IV Total CCS Stage 
(nº of cases)
CCS Stage I 5 2 0 1 I (8)
CCS Stage II 1 16 3 3 II (23)
CCS Stage III 0 4 10 8 III (22)
CCS Stage IV 1 1 2 25 IV (29)
Total PET Stage 
(nº of cases)
I (7) II (23) III (15) IV (37) 82
Figure 1 - A 22-year old male patient with conventional clinical stage II disease. A) FDG-PET coronal, axial and maximum intensity projection (MIP) 
images showed additional splenic lesions (arrows) not observed in the CT axial image (1). B) After two ABVD cycles, all lesions, including the splenic 
foci, disappeared; normal CT axial image (2). 
published to date came from Western Europe and North 
America. In this unselected patient cohort, there was a high 
frequency of advanced stages of the disease, mainly stage IV 
(35.4% by conventional staging and 43.9% by FDG-PET). 
This particularly distinctive stage distribution provided an 
opportunity to compare the usefulness of FDG-PET with 
conventional methods not only for staging nodal regions but 
also for extranodal sites.
Although the most important indication of FDG-PET 
is in the evaluation of the treatment response and post-
treatment evaluation of HL, all of which are matters beyond 
the scope of this paper, FDG-PET may be used in the initial 
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staging and may help classify patients into the appropriate 
stages of the disease, which can thus change the type and 
duration of the administered therapy. 
In this study, FDG-PET had a higher sensitivity than 
CT for the detection of nodal sites (87.8% vs. 61.6%, 
respectively), in agreement with other reports.3-6,10-13 
Metabolic testing with fluorine-18-fluorodeoxyglucose 
has also been described for detecting residual tumor or 
recurrence.14 The sensitivity of PET for detecting organ 
involvement was also higher than that determined for 
CT (96.2% vs. 40.0%, respectively), particularly for the 
evaluation of splenic involvement. The modified Ann-
Arbor system indicates that spleen infiltration is positive 
only when palpable splenomegaly is present or when there 
is radiological evidence gleaned from the CT results that 
are indicative of the presence of multiple focal defects. 
For detecting spleen lesions, the higher PET sensitivity 
compared to CT is probably related to the ability of FDG-
PET to detect metabolic changes in areas involved with HL 
before anatomical changes become visible.13
The diagnostic accuracy of FDG-PET for the detection 
of bone/BM involvement was also high when compared with 
results from the BM biopsy. FDG-PET identified all patients 
with a positive BM biopsy. In addition, another five patients 
were identified as positive using FDG-PET in bone/bone 
marrow sites but showed negative results in the BM biopsy. 
Only one of these discordant cases was considered as a 
false positive FDG-PET result due to the presence of a bone 
fracture. In all other discordant cases, the BM FDG-positive 
foci observed at staging disappeared during treatment. This 
discrepancy can be explained due to the existence of focal 
marrow infiltration by HL and biopsy sampling errors, even 
with bilateral sampling. As a consequence, the focal iliac 
BM involvement or infiltration at locations other than the 
posterior iliac crest could be missed by BM biopsy. Early 
studies have also demonstrated the usefulness of FDG-PET 
in the evaluation of BM involvement in lymphoma.15-18 In a 
recent meta-analysis, a good correlation was demonstrated 
between the results from FDG-PET and the BM biopsy 
in regard to the detection of BM involvement during the 
staging of patients with malignant lymphoma. However, the 
study involved a mixed population of different lymphoma 
types that have distinct patterns of BM infiltration and FDG 
avidity.19 Therefore, there is no consensus in regard to the 
idea that FDG-PET significantly reduces the need for BM 
biopsies as an initial staging procedure in HL stages II to 
IV.7
Computed tomography is the most commonly used 
imaging modality for staging HL due to its widespread 
availability and relatively low cost.12 Therefore, CT 
remains the standard imaging modality for initial staging of 
malignant lymphoma. However, an important limitation of 
CT is its failure to detect pathological changes in normal-
sized structures and lesions that have poor contrast with the 
surrounding tissue. An additional drawback of CT is that this 
method is not reliable for the detection of BM disease.12,20
Within recent years, FDG-PET has become the most 
important nuclear medicine and radiology imaging modality 
in the management of lymphoma. FDG-PET detects more 
disease sites and involved organs than conventional staging 
procedures, including CT, and it has a large influence on 
staging.12,20,21 
The major drawback of all studies that invoke FDG-
PET analyses for the staging of HL is the absence of a 
histological confirmation of all the FDG-avid lesions, which 
then requires the use of a reference standard instead of the 
gold standard. This limitation must also be considered in 
our study, due to the possibility of biasing the results in 
favor of PET. Consequently, caution must be invoked for 
cases that are upstaged by FDG-PET because it is well 
known that benign processes may cause FDG uptake, such 
as rebound thymic hyperplasia, infection, inflammation 
and muscular or brown fat uptake.7 It is also important to 
consider the normal bio-distribution of FDG and the lack 
of anatomical detail of PET scans alone. The FDG-PET/
CT fusion, using a combined PET/CT scanner, provides an 
accurate coregistration between the two modalities, allows 
for optimal interpretation of both modalities, and produces 
more accurate localization of the foci with increased FDG 
uptake than the stand-alone PET; this fusion may reduce the 
problems of physiological FDG uptake being misinterpreted 
as pathological and false localization of the disease.12 
However, the results of this study are similar to the studies 
reported using PET/CT equipment.9
Another limitation of the current study is the analysis 
of a patient population from a single health center. Several 
authors have extensively studied the performance of PET 
and PET/CT compared with CT over the past five years; as 
such, the compilation of multiple studies with larger series 
is required to substantiate literature results.
Besides the abovementioned limitations, numerous 
investigations have focused on the prospective impact 
of FDG-PET on staging and the choice of therapy in 
HL.19 These studies show that 11 to 41% of patients are 
upstaged by FDG-PET compared with conventional staging 
procedures and that 0 to 28% of patients are downstaged. 
The proportion of patients for whom the FDG-PET 
findings would potentially have changed the treatment 
strategy ranges from 3 to 25%. Similar to these 
aforementioned results, this study of a Brazilian population 
with a high rate of advanced stages of disease that have 
already been established by conventional methods indicates 
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that 20.7% of these patients would have been upstaged and 
10.9% would have been downstaged by implementation of 
the FDG-PET. If the stage were defined using the FDG-
PET results, it would have led to a change in the treatment 
strategy in 15.8% (13/82) of the patients, whereby seven 
patients would have received more aggressive treatment 
strategies and six patients would have received less 
aggressive treatment strategies.
CONCLUSION
The results of the present study indicate that FDG-PET 
has a high accuracy for the detection of nodal and extranodal 
HL and is superior to CT analysis alone. In addition, an 
excellent sensitivity for the detection of BM disease was 
observed using FDG-PET. The detection of additional lesions 
using FDG-PET imaging improves the accuracy of HL 
staging. Even in a Brazilian population that is characterized 
by a high rate of advanced stages of the disease using 
conventional methods, the FDG-PET most often upstages 
the disease and leads to a change in the treatment strategy in 
a significant number (16%) of patients. However, changes in 
the clinical stage based only upon FDG-PET results should 
be performed with caution, and subsequent biopsy of the 
site in question may be necessary depending on the clinical 
context. The results of the modification of HL therapy based 
on initial FDG-PET findings are still an open question that 
will only be answered with controlled clinical trials.
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